rwwine
Selling this company is really a head scratcher. Foley is basically a venture fund guy who found a niche with ZELTIQ Aesthetics and sold the company to Allergan about 8 years ago. I can't recall the deal but I remember it was very lucrative.
Zeltiq dealt with fat freezing and for awhile it was a exciting area of body sculpture.
I could see a PE or Venture coming in and take it over but I can't see a pharma interested unless they see a way to spin off the fintech and dermal side. I would also have to know what the cost of buying out the contracts for the pre and post manufacturing suppliers. (A lot).
Foley seems to have this company poised more along the lines of a sales organization than a pharma. They have a fintech that'll always be a loser, they are a distributor of the dermal fillers and procure both the frontside and backside Daxi work.
Can they make money? Absolutely, because I think they have the best product out there. They will never meet the kind of returns a pharma expects under the current organization.
News 
Market Data 
Discover 
